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Summary The newer herpesviruses are being increasingly recognized as signi¢cant opportunistic
pathogens in organ transplant recipients. Published data support the role of human herpesvirus-6 as a
potential cause of encephalitis and bonemarrow suppression in transplant setting. An association of human
herpesvirus-6 with fungal infections and cytomegalovirus infection has also been documented. Human
herpesvirus-7 also appears to be an immunomodulatory agent andmay facilitate the pathogenicity of
cytomegalovirus. Unlike human herpesviruses -6 and -7, human herepsvirus -8 is not ubiquitous; its
seroprevalence exhibits wide geographic variation. Human herpesvirus-8 has been causally associatedwith
post-transplant Kaposi's sarcoma. The complete spectrumof pathogenicity and ultimately the e¡ective
prophylaxis andmanagement of these viruses has yet to be fully elucidated.
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I N T R O D U C T I O N
Since 1986, three novel herpesviruses, human herpesviruses-
6, -7 and -8, have been discovered. It is nowknown that HHV-
8 is causally associated with post-transplant Kaposi's sarcoma.
However, controversy abounds regarding the precise role of
HHV-6 and HHV-7 in the post-transplant setting. The over-
view herein attempts to de¢ne the clinical relevance of these
herpesviruses as pathogens in transplant recipients.
H U M A N H E RP E S V I R U S - 6
Biological features
HHV-6 is a b-herpesvirus belonging to the genusRoseolovirus.
Phylogenetically, HHV-6 is most closely related to HHV-7
and cytomegalovirus (CMV); nucleotide sequencing has
shown 66% DNA sequence homology between CMV and
HHV-6 [1].HHV-6 is an enveloped virionwith an icosahedral
nucleocapsid of 162 capsomeres that contains large double-
stranded DNA [2,3]. The extracellular and cytoplasmic
nucleocapsids are surrounded by a thick tegument that is a dis-
tinctive morphologic feature of HHV-6 virions as compared
to the other herpesviruses.
On the basis of genomic DNA sequences, cell tropism and
protein expression, two distinct variants of HHV-6, desig-
nated the A (HHV-6A) and B (HHV-6B) variants, have been
described [4,5]. The two variants also di¡er in a number of
their biological properties. HHV-6A, as compared to HHV-
6B, is a more potent inducer of tumor necrosis factor-a and
other proin£ammatory cytokines. Most infections in trans-
plant recipients are due to HHV-6B; isolation of HHV-6A
from blood samples is distinctly rare in transplant patients.
Lack of detection of HHV-6A may imply either that HHV-
6A reactivation occurs infrequentlyor that reactivationmay be
limited to sites other than blood [6].
Pathogenesis
The primary target cells for HHV-6 are CD4 T-lympho-
cytes, a characteristic that it shares with HIV [7,8]. The pro-
pensity to preferentially infect CD4 T-cells di¡erentiates
HHV-6 from other DNAviruses. Unlike with HIV, however,
the CD4 molecule is not the membrane receptor for HHV-6
[9]. HHV-6 andHIVcan coinfect and simultaneously replicate
within the same CD4T-cells. Indeed, HHV-6 has been pro-
posed as a cofactor in the acceleration of HIV infection [7,10].
HHV-6 can upregulate CD4 expression and induce CD4
receptors on CD8 T-cells and natural killer (NK) cells, thus
making these cells susceptible to infection with HIV [11].
Although HHV-6most e¤ciently replicates in CD4T-cells,
its cellular host range also includes CD8 T-lymphocytes,
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NK cells, macrophages, megakaryocytes, glial cells, and
epithelial cells [12].
Besides directly infecting cells, HHV-6 is a powerful indu-
cer of cytokines, e.g. tumor necrosis factor-a, interferon-g,
and interleukin-1b [13,14]. It has been proposed that the
immunomodulatory and marrow suppressive e¡ects of HHV-
6may be partlydue to the production of these cytokines [15].
Epidemiology
Seroepidemiologic studies have shown that primary infection
due to HHV-6 is usually acquired during the ¢rst year of life,
saliva being the most likely mode of transmission. As with
other herpesviruses, HHV-6 persists in the host in a latent
form; seroprevalence in healthy adults exceeds 90% [16,17].
Although the precise site of latency in the body is not known,
the epithelial cells of the bronchial and salivary glands repre-
sent the most likely sites of latency [18]. Neurons and glial
cells are also believed to be sites where HHV-6may be latent.
Primary HHV-6 infection has been shown to be the cause
of roseola (exanthem subitum), a febrile illness of early child-
hood [19]. In immunocompetent adults, the virus has been
associated with an Epstein^Barr virus (EBV)-like mononu-
cleosis syndrome, autoimmune disorders (e.g. Sjogren's dis-
ease), non-Hodgkin's and Hodgkin's lymphomas, necrotizing
lymphadenitis, and focal encephalitis resembling herpes sim-
plex virus infection [12,20,21]. Apathogenic role of HHV-6 in
multiple sclerosis and other demyelinating disorders has also
been proposed.
HHV-6 infection has been documented in 38^55% of
renal, 31% of liver and 57% of lung transplant recipients [22^
28]. It should, however, be realized that most of these studies
utilized PCR-based assays for the diagnosis of HHV-6, and
these may have overestimated the incidence of HHV-6 infec-
tion. In bone marrow transplant recipients, HHV-6 infection
has been documented in 38^60% of patients [29^31].
Risk factors for HHV-6 in the post-transplant setting have
yet to be fully de¢ned. In a study in liver transplant recipients,
patients with hepatocellular carcinoma were more likely to
develop HHV-6 viremia than patients without it [32]. It was
proposed that the association between HHV-6 and hepatocel-
lular carcinoma is probably mediated through hepatotropic
viruses, e.g. hepatitis B and C viruses. HBV and HHV-6
encode gene products that can transactivate the long-terminal
repeat of viruses, e.g. HIV.Whether the hepatotropic viruses
can also facilitate the emergence of HHV-6 from latency by
transactivating its immediate early proteins remains to be pro-
ven.
Bone marrow transplant recipients with unrelated donors
were more likely to develop HHV-6 encephalitis, as compared
to those with HLA identical sibling donors [33]. In another
report, detection rates for HHV-6 DNA at 3 and 4weeks were
signi¢cantly higher in patients with allogeneic bone marrow
transplantation than in those with allogeneic peripheral blood
stem cell transplantation [34]. Unlike CMV, which occurs
considerably less frequently in autologous bonemarrow trans-
plant recipients, the incidence of HHV-6 infection is similar
in autologous and allogeneic bone marrow transplant recipi-
ents.
There are con£icting data on the role of rejection or aug-
mented immunosuppression in predisposing to HHV-6 infec-
tion. Reactivation of HHV-6 after OKT3 receipt has been
documented after renal transplantation [35]. In a study in liver
transplant recipients, CMVand HHV-6 DNA detection were
independently associated with allograft rejection [36]. An
inverse association between HHV-6 viremia and rejectionwas
documented in another report; patients with HHV-6 were less
likely to develop rejection, suggesting that HHV-6 may
indeed be an immunosuppressive virus [32].
Most HHV-6 infections occur between 2 and 4weeks after
transplantation; this characteristic timing of onset distin-
guishes HHV-6 from CMV, which usually occurs late, i.e. 6^
12weeks post-transplantation [37].
Transmission
Given the high HHV-6 rate of seropositivity in the general
population, most infections in transplant patients are proposed
to result from reactivation of the latent virus. Genomic analy-
sis of HHV-6 isolates from the blood of a patient, before and
after bone marrow transplantation, showed identical strains of
HHV-6 [31]. Donor transmission of HHV-6 has also been
documented. Following liver transplantation, primary HHV-
6 infection has been reported in 61% of the patients whowere
seronegative for HHV-6 prior to transplantation [27].
Although the precise mode of acquisition of primary HHV-6
infection in seronegative recipients is not known, donor allo-
graft is believed to be the likely source of transmission. HHV-
6 has been shown to develop latency in the kidney in vivo [38].
Furthermore, two renal transplant recipients who received the
allografts from the same cadaveric donor were documented to
have identical genomic patterns of their HHV-6 isolates [24].
Clinical manifestations
The precise clinical manifestations of HHV-6 in organ trans-
plant recipients remain to be fully elucidated; however, there is
accumulating evidence to suggest that HHV-6 may be a
pathogen in these patients.
Direct sequelae
Although fever of unknown origin, interstitial pneumonitis
and hepatitis have been reported in association with HHV-6,
bone marrow suppression and encephalitis are the most well
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documented clinical manifestations of HHV-6 in transplant
recipients (Table1). Acute and, less frequently, chronic myelo-
suppression due to HHV-6 have been reported [39]. Leuko-
cytes are the most common cell lineage suppressed (83%),
followed by platelets (67%) and red blood cells (50%). The
marrow suppressive e¡ect of HHV-6 is proposed to be
mediated by cytokines or virus-produced soluble factors [14].
A direct e¡ect of HHV-6 on hematopoietic progenitor cells
has also been demonstrated in vitro [40].
HHV-6 has been proposed to be the most neuroinvasive of
the herpesviruses. Several well-documented case reports of
HHV-6 encephalitis have been published, and at least three
controlled studies have documented an association between
HHV-6 and central nervous system (CNS) complications of
unidenti¢able etiology [41]. In a report of liver transplant reci-
pients, 15% (12/80) of the patients had mental status changes
of unknown etiology after transplantation [32]. Patients with
HHV-6 viremia had a signi¢cantly higher incidence of mental
status changes of unidenti¢able etiology (29%, 9/31) than
those without HHV-6 viremia (6%, 3/49, P 0.008). Among
338 bone marrow transplant patients, CNS symptoms devel-
oped in 24 (7.1%). HHV-6 DNA was detected in the cere-
brospinal £uid (CSF) in 23% (5/22) of the patients with CNS
symptoms [33]. None of the ¢ve cases with HHV-6 DNA
detected in CSF samples had an identi¢ed cause of their CNS
symptoms, and none of the 11 cases with known etiology of
CNS symptoms had HHV-6 DNA in the CSF (P 0.03).
Allogeneic bone marrow transplant recipients who received
CD3-speci¢c monoclonal antibody (anti-CD3) were more
likely to develop encephalitis than patients who did not
receive anti-CD3 (P 0.008) [42]. Anti-CD3 recipients had a
higher incidence of HHV-6 viremia and a signi¢cantly higher
HHV-6 viral load in the serum [42]. After adjusting for anti-
CD3 therapy, HHV-6 itself was signi¢cantly associated with
encephalitis (P 0.009) [42].
Mental status changes, ranging from confusion to coma,
seizure and headache, are the predominant clinical manifesta-
tions of HHV-6. Focal neurologic ¢ndings are rare. CSF pleo-
cytosis and abnormal neuroimaging ¢ndings are
characteristically absent. Rarely, low-attenuation CNS
lesions, mimicking immunosuppression-associated leukoen-
cephalopathy, may be seen [41].
Indirect sequelae
HHV-6 has been described as an immunomodulatory and
immunosuppressive virus that may facilitate superinfections
with other opportunistic organisms in transplant recipients,
particularly CMV [13,27,37,39]. Primary HHV-6 infection
was identi¢ed as a signi¢cant risk factor for the development
of symptomatic CMV infection, including tissue-invasive
CMVdisease in liver transplant recipients [27]. In renal trans-
plant recipients at risk for primary CMV infection, HHV-6
infectionwas signi¢cantly associated with the development of
CMVviral syndrome and CMVhepatitis [39].
HHV-6 infection was an independently signi¢cant predic-
tor of invasive fungal infection in two studies in liver trans-
plant recipients. Liver transplant recipients with HHV-6 had a
signi¢cantly higher mortality; the independent association
between HHV-6 and late mortality approached statistical sig-
ni¢cance in this study [32].
Diagnosis
Serologic, virologic and in situ immunohistochemistry assays
have been utilized for the diagnosis of HHV-6. For the serolo-
gic diagnosis of HHV-6, enzyme immunoassays have proven
more sensitive than the £uorescence assays [43]. As with all
herpesviruses (that establish latency), serologic tests, while
useful for the determination of seroprevalence, may not be
reliable indicators of active infection. Antigenic cross-reactiv-
ity or concomitant infectionwith other herpesvirus may con-
found the speci¢city of the serologic assays or the
interpretation of changes in HHV-6 antibody titers. IgM per se
is also not a reliable marker for HHV-6 infection, since most
cases con¢rmed by culture or seroconversion have no detect-
able IgM [43]. Furthermore, up to 5% of healthy adults may
demonstrate IgMpositivity at any time [43].
HHV-6 induces a characteristic cytopathic e¡ect in primary
lymphocyte culture, with`large ballooning' refractile cells and
loss of normal lymphocyte clumping. Con¢rmation of HHV-
6 in cell culture, however, must be performed by using HHV-
6-speci¢c reagents and not merely by the cytopathic e¡ect.
HHV-6 isolation in cell culture is labor-intensive and requires
5^21days for detection. A rapid shell vial (early antigen) assay
has been developed that can detect HHV-6 within 72 h [37].
This assay is analogous to the shell vial assay for the diagnosis
of CMV. In bone marrow and liver transplant recipients, a
Table 1 Association of HHV-6 with clinical sequelae and the level of
supportive evidence
Supportive evidence from cohort studies
Encephalitis
Bone marrow suppression
Association with fungal infections
Association with cytomegalovirus infection
Evidence from case reports or case series
Pneumonitis
Rash
Hepatitis
Gastroduodenitis
Proposed association with con¯icting supportive evidence
Association with allograft rejection
Association with graft versus host disease
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sensitivityof 86% and a speci¢cityof100%have been demon-
stratedwith this assay when compared to the conventional cell
culture [44].
Qualitative PCR for the diagnosis of HHV-6 is limited by
the fact that it can detect latent virus. Latently infected periph-
eral blood mononuclear cells, however, contain fewer than 10
HHV-6 genomes per 106 cells. Nevertheless, PCR has other
advantages; PCRpositivity in cell-free specimens can be diag-
nostically useful. Furthermore, HHV-6 variant discrimina-
tion can be readily accomplished by PCR.
Immunohistochemical stains for detecting HHV-6 in for-
malin-¢xed para¤n-embedded tissue are also available.
Immunohistochemical staining of tissues with murine mono-
clonal antibody reactive against the structural protein p101 of
variant B and structural protein gp82 of variant A detects cells
productively and not latently infectedwith HHV-6.
Although viral inclusion-bearing cells may occasionally be
visualized in histopathologic samples [39], HHV-6 character-
istically elicits little in£ammatory response. Multinucleated
giant cells (similar to the cytopathogenic e¡ect caused by
HHV-6 in humanT-lymphocytes in vitro) and enveloped vir-
ions, with a prominent tegument visualized electronmicros-
copically in the tissue, were proposed as morphologic criteria
to consider the possibility of tissue-invasive HHV-6 disease
[45].
Management
The antiviral susceptibilities of HHV-6 resemble those of
CMV, i.e. it is sensitive to ganciclovir and foscarnet and less so
to acyclovir [46^49]. Serum levels (1.8^3.6mg/L) following
low-dose acyclovir (200mg) are inadequate to suppress HHV-
6. High-dose acyclovir (800mg) can achieve plasma concen-
trations of approximately 1.6mg/L, which may be partially
suppressive for some HHV-6 variant A strains. However, the
mean IC50s of HHV-6A and HHV-6B variants are 20 mM and
37 mM, respectively [47,48,50^52]. Thus, acyclovir, even in
high doses, may not be suppressive for most HHV-6 isolates.
The L-valine ester of acyclovir, valacyclovir, upon administra-
tion is rapidly converted to acyclovir, achieving peak plasma
levels of 38 mM after 200mg of valacyclovir.These concentra-
tionswould be e¡ective formost HHV-6Avariants.
Peak serum concentrations following intravenous ganciclo-
vir (5mg/kg) average 31^43 mM and should be adequate to
suppress HHV-6 [47,48,52,53]. The IC50 of foscarnet for
HHV-6 ranges between 49 and 67 mM; these concentrations
are readily achievable with a foscarnet infusion of 90mg/kg
[52,53]. Cidofovir also demonstrates in vitro activity against
HHV-6.
Although some reports have documented the successful
treatment of transplant recipients with HHV-6 infection, the
indications for therapy, the drug of choice and the e¤cacy of
antiviral therapy for HHV-6 have not been adequately assessed
in transplant patients. In patients with HHV-6 encephalitis,
curewas documented in seven of eight who received ganciclo-
vir or foscarnet for r7 days as compared to none of four in
those who did not receive these drugs or received them for
<7 days (P 0.01) [41]. Issues concerning prophylaxis, i.e.
indications for prophylaxis, timing of initiation, duration,
choice of antiviral agent or the e¤cacy of prophylaxis for
HHV-6, remain to be resolved.
H U MA N H E R PE S V IR U S - 7
Infection due to HHV-7, like that due to HHV-6, is ubiqui-
tous. Primary infection due to HHV-7 also occurs during
childhood, albeit at a slightly later age than with HHV-6.
HHV-7 not only exhibits selective tropism for CD4 T-lym-
phocytes, but also utilizes the CD4 molecule as its receptor. A
causal association between HHV-7 and clinical illness, how-
ever, has not been established in the transplant or non-trans-
plant setting.
Unlike with HHV-6, a bimodal peak of HHV-7 DNA
detection was documented in one study in bone marrow
transplant recipients.The ¢rst peak occurred at 3^4weeks, and
the second 9^10weeks after transplantation. Patients with
CMVdisease weremore likely to have HHV-7 DNAdetection
than those with asymptomatic CMV infection (31% versus
0%, P 0.13) [54]. In a study in renal transplant recipients,
patients with CMVand HHV-7 coinfection were more likely
to have CMV disease than those with CMV infection only
[55]. In liver transplant recipients, however, no pathogenic
e¡ect of HHV-7was documented [36].
H U MA N H E R PE S V IR U S - 8
HHV-8 or Kaposi's sarcoma-associated herpesvirus (KSHV)
has been causally associated with all forms of Kaposi's sarcoma
(KS), including post-transplant KS. KSHV is a g-herpesvirus
belonging to the genus Rhadinovirus. It is most closely related
to herpesvirus saimiri, with which it has 51% DNA sequence
homology; these herpesviruses are transforming viruses cap-
able of causing tumors in their natural hosts.
Biological features
KSHV is unique among herpesviruses in that it contains an
unprecedented number of genes transduced from the host cel-
lular genomes during its evolution, a phenomenon known as
molecular piracy [56].While less important for viral replica-
tion, three genes encode for cellular homologs that induce
angiogenesis, regulate antiviral immunity and alter cellular
growth [56]. The histopathologic hallmark of KS is the pre-
sence of spindle cells. A majority of these cells stain positive
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for endothelial cell markers; however, some cells express pro-
teins characteristic of smooth muscle cells, macrophages or
dendritic cells. These data suggest that KS spindle cells may
indeed be derived from a pluripotent mesenchymal progeni-
tor cell [56].
There is some debate over whether KS is a true malignancy
or a cytokine-driven hyperplasia. KSHV is a potent inducer of
cytokines, e.g. IL-6, basic ¢broblast growth factor and IFN-g,
that have been shown to be angiogenic. KS spindle cells pro-
duce IL-6, and exogenous IL-6 can enhance the proliferation
of KS cells in culture, thus leading many to believe that KS
may be a cytokine-driven lesion.
Although most KS lesions in transplant recipients are
believed to result from reactivation of latent virus, transmis-
sion by transplanted allograft has been documented. Serocon-
version occurred a mean of 5months after transplantation and
preceded KS by 11.5months in another study [57]. Anatomic
distribution of KS in an autopsy study and HLA haplotyping
suggested that KS arose in the stromal endothelial cells of the
donor liver in a liver transplant recipient [58].
Epidemiology and clinical manifestations
The incidence of KS in transplant recipients largely parallels
the geographic seroprevalence of KSHV (Table 2). Conse-
quently, wide geographic variations in the rate of KS have
been documented. In areas of low seroprevalence of KSHV,
e.g. the USA, KS has been observed in<1% of the transplant
recipients and accounts for 3^10% of all malignancies in trans-
plant recipients. On the other hand, in South Africa and Saudi
Arabia, up to 5% of the transplant recipients have been docu-
mented to develop KS, and KS accounts for 59^87% of the
post-transplant malignancies [57,59^61]. The striking male
predominance of KS lesions in the non-transplant setting is
less pronounced in transplant recipients, the male/female ratio
in transplant recipients being 2^3 : 1.
KS is one of the earliest post-transplant malignancies to
occur in transplant recipients. The median time to onset was
22months for KS, 32months for lymphomas, and 69months
for epithelial malignancies [62]. Liver transplant recipients in
one study had a higher frequency of KS than other organ
transplant recipients [63]. Notably, KS has only rarely been
documented in bonemarrow transplant recipients.
Although skin is the most commonly involved site of KS,
up to 40% of the transplant recipients may develop visceral
lesions, including gastrointestinal, pulmonary, bladder and
laryngeal KS. Gastrointestinal involvement may often be
occult or associated with non-speci¢c gastrointestinal symp-
toms and bleeding. Occasionally, perforation, obstruction and
protein-losing enteropathy as a result of lymphatic obstruc-
tion have been reported.
Management
Although regression of KS with reduction or cessation of
immunosuppression has been reported in all forms of KS,
higher remission rates have been documented with non-visc-
eral as compared to visceral lesions. However, 50% of the
patients have lost their grafts in response to cessation of immu-
nosuppression. In patients with disseminated or visceral KS
that failed to respond to modi¢cation of immunosuppression,
combination chemotherapy has proven e¡ective in some
reports [64]. Retransplantation in renal allograft recipients in
this setting has nearly always led to recurrence of KS lesions.
The role of a herpesvirus in the pathogenesis of KS and the
fact that lytically infected cells exist in KS lesions have impli-
cations for treatment of KS with antiviral agents. However,
only limited experience with antiviral therapy exists in this
setting. Nucleoside analogs, e.g. acyclovir and penciclovir,
have minimal in vitro activity against KSHV.While the virus
is susceptible to ganciclovir and foscarnet, acyclic nucleoside
phosphonate analogs, cidofovir and HPMPA ((S)-1-(3-
hydroxy-2-phosphonylmethoxypropyadenine), are potent
inhibitors of HHV-8 DNA synthesis [65]. Adefovir blocked
HHV-8 DNA replication at a four-fold lower concentration
than did foscarnet.
In the HIV setting, a signi¢cant reduction in the risk of KS
has been reported in patients who received ganciclovir. Abate-
ment of KS in association with cidofovir treatment has also
been reported in HIV-infected patients [66]. In four thoracic
organ transplant recipients who received cidofovir because of
KS recurrence or intolerance after cytotoxic chemotherapy,
clearance of KSHV was documented from blood in two of
two, and from skin lesions in two of four patients [67].
Furthermore, clinical improvement of gastric KS lesions was
documented in one patient [67].
Prophylaxis for KS is a worthy goal in patients from highly
endemic areas. Should e¡ective antiviral strategies become
available in the future, patients with seroconversion or those
Table 2 Geographic variations in the incidence of Kaposi's sarcoma
in organ transplant recipients [60,63,68±70]
Country
Incidence of
Kaposi's sarcoma
Proportion of all malignancies
due to Kaposi's sarcoma
USA 0.5% 3±10%
France 0.6% 8.3%
Italy 1.6% NA
Israel 2.4% NA
South Africa 4% 59%
Saudi Arabia 5.3% 87%
NA, data not available.
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with increasing KSHV titers by qualitative PCR may be can-
didates for prophylaxis.
C O N C L U S IO N
Although incontrovertible evidence of pathogenicity has
only been documented thus far for human HHV-8, emerging
data suggest that all of the novel b-herpesviruses may be clini-
cally relevant opportunistic pathogens in transplant recipients.
The indirect sequelae of HHV-6 and -7 infections are intri-
guing. It is conceivable that the bene¢cial e¡ect of antiviral
prophylaxis for CMV in transplant recipients could in part
have been mediated through its e¡ect on the newer b-herpes-
viruses. In this regard, future trials for CMV chemoprophy-
laxis may consider monitoring the e¡ect of antiviral agents on
HHV-6 and -7 as well. Such data would further elucidate the
pathogenicity of these viruses in transplant recipients.
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